TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions
TGTX Stock Forecast
TG Therapeutics stock forecast is as follows: an average price target of $26.40 (represents a 11.25% upside from TGTX’s last price of $23.73) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
TGTX Price Target
The average price target for TG Therapeutics (TGTX) is $26.40 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $49.00 to $16.00. This represents a potential 11.25% upside from TGTX's last price of $23.73.
TGTX Analyst Ratings
According to 6 Wall Street analysts, TG Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TGTX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TG Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | -2.82% | -15.72% |
| May 03, 2024 | Edward White | H.C. Wainwright | $49.00 | $16.42 | 198.42% | 106.49% |
| Feb 07, 2023 | - | Cantor Fitzgerald | $24.00 | $18.48 | 29.87% | 1.14% |
| Dec 30, 2022 | - | Evercore ISI | $16.00 | $11.83 | 35.25% | -32.57% |
| Dec 29, 2022 | Edward White | H.C. Wainwright | $24.00 | $8.46 | 183.69% | 1.14% |
| Apr 19, 2022 | - | Goldman Sachs | $5.00 | $7.26 | -31.13% | -78.93% |
| Apr 18, 2022 | Mayank Mamtani | Telsey Advisory | $23.00 | $6.92 | 232.37% | -3.08% |
The latest TG Therapeutics stock forecast, released on Aug 06, 2024 by Corinne Jenkins from Goldman Sachs, set a price target of $20.00, which represents a -2.82% decrease from the stock price at the time of the forecast ($20.58), and a -15.72% decrease from TGTX last price ($23.73).
TG Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $20.00 | $34.50 |
| Last Closing Price | $23.73 | $23.73 | $23.73 |
| Upside/Downside | -100.00% | -15.72% | 45.39% |
In the current month, the average price target of TG Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TG Therapeutics's last price of $23.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| May 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 02, 2023 | Goldman Sachs | Sell | Neutral | Upgrade |
| Dec 30, 2022 | Jefferies | Buy | Buy | Hold |
| Dec 30, 2022 | Goldman Sachs | Sell | Sell | Hold |
| Dec 30, 2022 | B. Riley Securities | Buy | Buy | Hold |
| Dec 30, 2022 | Evercore ISI | Outperform | Outperform | Hold |
| Dec 29, 2022 | B. Riley | Buy | Buy | Hold |
| Dec 29, 2022 | Morgan Stanley | Underperform | Underperform | Hold |
| Dec 29, 2022 | H.C. Wainwright | Buy | Buy | Hold |
TG Therapeutics's last stock rating was published by Goldman Sachs on Aug 06, 2024. The company gave TGTX a "Neutral" rating, the same as its previous rate.
TG Therapeutics Financial Forecast
TG Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $43.97M | $165.81M | $16.07M | $7.80M | $80.00K | $94.00K | - | $2.02M | $2.32M | $2.03M | $1.54M | $793.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K |
| Avg Forecast | $154.15M | $133.94M | $109.33M | $96.21M | $98.42M | $81.23M | $65.92M | $54.60M | $40.06M | $23.91M | $17.39M | $3.38M | $1.60M | $1.46M | $175.43K | $2.08M | $2.24M | $2.97M | $3.60M | $820.29K | $19.00K | $19.00K | $22.80K | $22.80K | $22.80K | $34.50K | $19.00K | $25.33K |
| High Forecast | $162.14M | $140.89M | $114.99M | $101.20M | $103.52M | $83.84M | $69.34M | $57.43M | $40.18M | $25.15M | $18.29M | $3.55M | $1.69M | $1.53M | $175.43K | $2.20M | $2.37M | $3.14M | $3.82M | $869.01K | $20.13K | $20.13K | $24.15K | $24.15K | $24.15K | $36.55K | $20.13K | $26.84K |
| Low Forecast | $145.55M | $126.48M | $103.23M | $90.84M | $92.93M | $77.59M | $62.25M | $51.56M | $39.88M | $22.58M | $16.42M | $3.19M | $1.51M | $1.37M | $175.43K | $1.86M | $2.00M | $2.66M | $3.23M | $734.22K | $17.01K | $17.01K | $20.41K | $20.41K | $20.41K | $30.88K | $17.01K | $22.67K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 6.93% | 0.92% | 2.31% | 0.05% | 0.06% | - | 0.97% | 1.04% | 0.68% | 0.43% | 0.97% | 2.00% | 2.00% | 1.67% | 1.67% | 1.67% | 1.10% | 2.00% | 1.50% |
TG Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $54.60M, with a low forecast of $51.56M, and a high forecast of $57.43M. TGTX's average Quarter revenue forecast represents a 24.18% increase compared to the company's last Quarter revenue of $43.97M (Dec 23).
TG Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-12.48M | $114.78M | $-43.98M | $-36.39M | $-50.13M | $-34.04M | - | $-66.22M | $-92.18M | $-84.52M | $-76.81M | $-88.67M | $-86.87M | $-85.51M | $-50.62M | $-49.88M | $-37.65M | $-60.37M | $-35.11M | $-35.13M |
| Avg Forecast | $-120.54M | $-104.74M | $-85.49M | $-75.23M | $-76.96M | $-63.52M | $-51.55M | $-42.70M | $-31.33M | $-18.70M | $-13.60M | $-2.64M | $-1.25M | $-78.03M | $-137.18K | $-49.39M | $-1.75M | $-70.94M | $-59.21M | $-57.73M | $-14.86K | $-66.09M | $-17.83K | $-17.83K | $-17.83K | $-26.98K | $-14.86K | $-19.81K |
| High Forecast | $-113.82M | $-98.90M | $-80.72M | $-71.04M | $-72.67M | $-60.68M | $-48.68M | $-40.32M | $-31.19M | $-17.66M | $-12.84M | $-2.49M | $-1.18M | $-62.43M | $-137.18K | $-39.51M | $-1.57M | $-56.75M | $-47.36M | $-46.18M | $-13.30K | $-52.87M | $-15.96K | $-15.96K | $-15.96K | $-24.15K | $-13.30K | $-17.73K |
| Low Forecast | $-126.79M | $-110.17M | $-89.92M | $-79.13M | $-80.95M | $-65.56M | $-54.22M | $-44.91M | $-31.42M | $-19.67M | $-14.31M | $-2.78M | $-1.32M | $-93.64M | $-137.18K | $-59.26M | $-1.86M | $-85.13M | $-71.05M | $-69.27M | $-15.74K | $-79.30M | $-18.89K | $-18.89K | $-18.89K | $-28.58K | $-15.74K | $-20.98K |
| Surprise % | - | - | - | - | - | - | - | - | 0.40% | -6.14% | 3.23% | 13.77% | 39.96% | 0.44% | - | 1.34% | 52.63% | 1.19% | 1.30% | 1.54% | 5847.34% | 1.29% | 2839.31% | 2797.97% | 2111.45% | 2237.64% | 2363.40% | 1773.59% |
5 analysts predict TGTX's average Quarter EBITDA for Dec 23 to be $-31.33M, with a high of $-31.19M and a low of $-31.42M. This is -127.29% lower than TG Therapeutics's previous annual EBITDA (Sep 23) of $114.78M.
TG Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-14.42M | $113.93M | $-47.61M | $-38.63M | $-53.92M | $-36.67M | - | $-71.15M | $-93.73M | $-86.15M | $-79.50M | $-92.05M | $-89.65M | $-88.60M | $-54.92M | $-51.99M | $-41.18M | $-63.00M | $-36.88M | $-35.62M |
| Avg Forecast | $58.99M | $44.64M | $23.12M | $17.54M | $13.44M | $3.64M | $-7.27M | $-9.57M | $-15.99M | $9.11M | $-40.09M | $-57.79M | $-43.22M | $-79.06M | $-70.18M | $-51.45M | $-90.86M | $-71.87M | $-60.51M | $-59.00M | $-85.65M | $-67.36M | $-48.37M | $-51.23M | $-65.54M | $-48.29M | $-58.19M | $-62.25M |
| High Forecast | $62.96M | $47.65M | $24.67M | $18.72M | $14.34M | $4.86M | $-6.74M | $-8.87M | $-13.32M | $9.73M | $-37.19M | $-53.60M | $-40.09M | $-63.25M | $-70.18M | $-41.16M | $-78.47M | $-57.50M | $-48.41M | $-47.20M | $-73.97M | $-53.89M | $-41.77M | $-44.24M | $-56.60M | $-41.71M | $-50.25M | $-53.75M |
| Low Forecast | $54.71M | $41.40M | $21.44M | $16.27M | $12.46M | $2.43M | $-7.76M | $-10.21M | $-17.32M | $8.45M | $-42.79M | $-61.68M | $-46.13M | $-94.87M | $-70.18M | $-61.74M | $-97.88M | $-86.25M | $-72.61M | $-70.80M | $-92.27M | $-80.83M | $-52.10M | $-55.18M | $-70.60M | $-52.02M | $-62.69M | $-67.05M |
| Surprise % | - | - | - | - | - | - | - | - | 0.90% | 12.50% | 1.19% | 0.67% | 1.25% | 0.46% | - | 1.38% | 1.03% | 1.20% | 1.31% | 1.56% | 1.05% | 1.32% | 1.14% | 1.01% | 0.63% | 1.30% | 0.63% | 0.57% |
TG Therapeutics's average Quarter net income forecast for Dec 23 is $-15.99M, with a range of $-17.32M to $-13.32M. TGTX's average Quarter net income forecast represents a -114.03% decrease compared to the company's last Quarter net income of $113.93M (Sep 23).
TG Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $31.15M | $26.50M | $36.38M | $29.65M | $28.26M | $17.50M | - | $22.50M | $56.46M | $34.90M | $34.02M | $26.76M | $43.86M | $35.30M | $14.43M | $14.26M | $7.06M | $2.91M | $2.72M | $2.34M |
| Avg Forecast | $30.57B | $26.57B | $21.68B | $19.08B | $19.52B | $16.11B | $13.07B | $10.83B | $7.95B | $4.74B | $3.45B | $670.15M | $318.16M | $288.71M | $34.79M | $412.66M | $444.22M | $588.55M | $714.97M | $162.69M | $3.77M | $3.77M | $4.52M | $4.52M | $4.52M | $6.84M | $3.77M | $5.02M |
| High Forecast | $32.16B | $27.94B | $22.81B | $20.07B | $20.53B | $16.63B | $13.75B | $11.39B | $7.97B | $4.99B | $3.63B | $704.88M | $334.65M | $303.67M | $34.79M | $437.18M | $470.61M | $623.52M | $757.45M | $172.35M | $3.99M | $3.99M | $4.79M | $4.79M | $4.79M | $7.25M | $3.99M | $5.32M |
| Low Forecast | $28.87B | $25.08B | $20.47B | $18.02B | $18.43B | $15.39B | $12.35B | $10.23B | $7.91B | $4.48B | $3.26B | $632.78M | $300.42M | $272.61M | $34.79M | $369.36M | $397.61M | $526.80M | $639.95M | $145.62M | $3.37M | $3.37M | $4.05M | $4.05M | $4.05M | $6.12M | $3.37M | $4.50M |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.01% | 0.01% | 0.04% | 0.09% | 0.06% | - | 0.05% | 0.13% | 0.06% | 0.05% | 0.16% | 11.64% | 9.37% | 3.19% | 3.15% | 1.56% | 0.43% | 0.72% | 0.47% |
TG Therapeutics's average Quarter SG&A projection for Mar 24 is $10.83B, based on 4 Wall Street analysts, with a range of $10.23B to $11.39B. The forecast indicates a 34662.42% rise compared to TGTX last annual SG&A of $31.15M (Dec 23).
TG Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.10 | $0.80 | $-0.34 | $-0.28 | $-0.39 | $-0.27 | - | $-0.53 | $-0.71 | $-0.65 | $-0.60 | $-0.70 | $-0.72 | $-0.74 | $-0.49 | $-0.49 | $-0.43 | $-0.70 | $-0.42 | $-0.44 |
| Avg Forecast | $0.37 | $0.28 | $0.14 | $0.11 | $0.08 | $0.02 | $-0.05 | $-0.06 | $-0.10 | $0.06 | $-0.25 | $-0.36 | $-0.27 | $-0.35 | $-0.48 | $-0.61 | $-0.64 | $-0.57 | $-0.52 | $-0.56 | $-0.60 | $-0.41 | $-0.34 | $-0.36 | $-0.46 | $-0.34 | $-0.41 | $-0.43 |
| High Forecast | $0.39 | $0.30 | $0.15 | $0.12 | $0.09 | $0.03 | $-0.04 | $-0.06 | $-0.08 | $0.06 | $-0.23 | $-0.34 | $-0.25 | $-0.33 | $-0.48 | $-0.53 | $-0.55 | $-0.49 | $-0.45 | $-0.48 | $-0.52 | $-0.36 | $-0.29 | $-0.31 | $-0.40 | $-0.29 | $-0.35 | $-0.38 |
| Low Forecast | $0.34 | $0.26 | $0.13 | $0.10 | $0.08 | $0.02 | $-0.05 | $-0.06 | $-0.11 | $0.05 | $-0.27 | $-0.39 | $-0.29 | $-0.38 | $-0.48 | $-0.66 | $-0.68 | $-0.61 | $-0.56 | $-0.60 | $-0.64 | $-0.45 | $-0.36 | $-0.39 | $-0.49 | $-0.36 | $-0.44 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 14.00% | 1.35% | 0.77% | 1.44% | 0.76% | - | 0.87% | 1.12% | 1.14% | 1.15% | 1.26% | 1.20% | 1.79% | 1.45% | 1.37% | 0.94% | 2.07% | 1.03% | 1.01% |
According to 5 Wall Street analysts, TG Therapeutics's projected average Quarter EPS for Dec 23 is $-0.10, with a low estimate of $-0.11 and a high estimate of $-0.08. This represents a -112.53% decrease compared to TGTX previous annual EPS of $0.80 (Sep 23).
TG Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| BTAI | BioXcel Therapeutics | $0.68 | $13.00 | 1811.76% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| TGTX | TG Therapeutics | $23.73 | $26.40 | 11.25% | Buy |
| EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
TGTX Forecast FAQ
Is TG Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, TG Therapeutics (TGTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of TGTX's total ratings.
What is TGTX's price target?
TG Therapeutics (TGTX) average price target is $26.4 with a range of $16 to $49, implying a 11.25% from its last price of $23.73. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will TG Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TGTX stock, the company can go up by 11.25% (from the last price of $23.73 to the average price target of $26.4), up by 106.49% based on the highest stock price target, and down by -32.57% based on the lowest stock price target.
Can TG Therapeutics stock reach $40?
TGTX's highest twelve months analyst stock price target of $49 supports the claim that TG Therapeutics can reach $40 in the near future.
What are TG Therapeutics's analysts' financial forecasts?
TG Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $300.18M (high $314.14M, low $284.33M), average EBITDA is $-235M (high $-222M, low $-246M), average net income is $243.6K (high $3.58M, low $-3.08M), average SG&A $59.53B (high $62.3B, low $56.39B), and average EPS is $0.00153 (high $0.0225, low $-0.0193). TGTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $493.63M (high $519.21M, low $466.1M), average EBITDA is $-386M (high $-364M, low $-406M), average net income is $144.28M (high $154M, low $133.82M), average SG&A $97.9B (high $102.97B, low $92.44B), and average EPS is $0.905 (high $0.966, low $0.839).
Did the TGTX's actual financial results beat the analysts' financial forecasts?
Based on TG Therapeutics's last annual report (Dec 2023), the company's revenue was $233.66M, beating the average analysts forecast of $84.75M by 175.71%. Apple's EBITDA was $20.63M, missing the average prediction of $-66.272M by -131.13%. The company's net income was $12.67M, missing the average estimation of $-105M by -112.10%. Apple's SG&A was $122.71M, missing the average forecast of $16.81B by -99.27%. Lastly, the company's EPS was $0.0853, missing the average prediction of $-0.657 by -112.98%. In terms of the last quarterly report (Dec 2023), TG Therapeutics's revenue was $43.97M, beating the average analysts' forecast of $40.06M by 9.75%. The company's EBITDA was $-12.485M, missing the average prediction of $-31.329M by -60.15%. TG Therapeutics's net income was $-14.416M, missing the average estimation of $-15.985M by -9.82%. The company's SG&A was $31.15M, missing the average forecast of $7.95B by -99.61%. Lastly, the company's EPS was $-0.1, missing the average prediction of $-0.1 by -0.27%